AEYE Health Data, Analytics & Interoperability: Features, Pricing & Alternatives

FDA-cleared autonomous AI that reads retinal images on the spot to screen for diabetic retinopathy.

Data, Analytics & Interoperability Hybrid

AEYE Health offers FDA-cleared autonomous AI for diabetic retinopathy screening using portable and tabletop retinal cameras, enabling point-of-care diagnosis in primary care.

  • Founded: 2019
  • HQ: New York, NY, USA
  • Best for: Primary care, endocrinology, and health systems that want to capture diabetic retinopathy screening revenue in-house instead of referring out.
  • Our take

    AEYE Health is best suited for Primary care, endocrinology, and health systems that want to capture diabetic retinopathy screening revenue in-house instead of referring out.. FDA-cleared autonomous read removes the specialist over-read bottleneck..

    Main limitation: no public pricing, so buyers cannot budget without a sales cycle.. Scored 3.1/5 across the EHRAtlas scorecard.

    AEYE Health Overview

    AEYE Health is a medical AI company focused on autonomous retinal screening, best known for AEYE-DS, which it describes as the only FDA-cleared solution offering instant AI diabetic retinopathy diagnosis with handheld or tabletop cameras. The system performs a one-minute autonomous exam using a single image per eye, produces an on-the-spot diagnostic report, and requires no physician interpretation, allowing primary care physicians to screen patients during a routine visit instead of referring them to a specialist.

    The product line pairs the AEYE-DS diagnostic AI with two camera configurations: the Aurora AEYE portable camera, billed as the first and only FDA-cleared AI-powered diabetic retinopathy solution for a portable camera, and a robotic tabletop camera designed for ease of use. The company reports sensitivity of 92%-93% and specificity of 89%-94% for the portable configuration, and 93% sensitivity and 91% specificity for the tabletop configuration, with a success rate above 99% in both cases. A separate offering, AEYE-X, extends AI-based diagnostic screening to a broad range of diseases using retinal images.

    The company positions its technology around closing care gaps in diabetic retinopathy, noting that the exam is reimbursable under CPT 92229 and supports HEDIS gap closure. It cites the scale of the underlying problem, including more than 830 million people worldwide and over 40 million people in the US living with diabetes, at least 85% of people over 40 with diabetes developing diabetic retinopathy, and fewer than 50% of US patients with diabetes adhering to annual eye exams. The site does not disclose founding date, headquarters, ownership, or detailed company history.

    Reported scale: More than 830M people in the world live with diabetes; Over 40M people in the US live with diabetes; At least 85% of people over 40 with diabetes will develop diabetic retinopathy.

    AEYE Health Evaluation

    Scored against the same 7 dimensions used in the EHRAtlas Scorecard. 0 = not enough public information to score. These are analyst estimates, not endorsements — verify during a demo. Buyers should validate capabilities, pricing, implementation requirements, and fit during vendor evaluation.

    Product Maturity 3/5

    Age, customer base, feature depth.

    Founded 2019 and cleared by FDA in 2022, so the product has several years of commercial life, but the installed base is smaller than legacy imaging vendors and the company is still in scaling mode. Feature depth is narrow by design: one cleared indication, one reimbursement pathway.

    Target Market 4/5

    Solo/small, mid, enterprise, or niche.

    Deliberately aimed at non-ophthalmic settings where the diabetic eye exam gap actually lives: primary care, endocrinology, and multi-site health systems. That is a large, underpenetrated market, though adoption depends on clinics buying cameras and changing workflow.

    Key Differentiators 4/5

    What sets it apart from alternatives.

    Autonomous read with no specialist over-read and support for handheld cameras are differentiators versus systems tied to a single tabletop device. It is not unique in the autonomous category, though, since IDx-DR and EyeArt hold similar clearances.

    Integrations 3/5

    Systems it connects to out of the box.

    Epic connectivity is the headline integration, which matters because most target customers are Epic shops. Beyond that, published detail on other EHRs, image archives, or referral workflows is limited, so treat broader integration claims cautiously.

    Compliance & Certifications 4/5

    HIPAA, SOC 2, ONC, FDA, other.

    FDA 510(k) clearance for autonomous diabetic retinopathy screening is the certification that counts here, and it is documented. ONC certification is not applicable to a diagnostic AI and is absent. HIPAA and SOC 2 posture is not publicly documented, which is a gap for enterprise security reviews.

    Support Model 2/5

    In-house vs outsourced, SLAs, channels.

    No published support tiers, SLAs, or service channels. Camera partners and channel distributors may carry part of the field service burden, but AEYE Health does not document an escalation model, which makes procurement diligence harder.

    Pricing Model 2/5

    How it charges and what the entry point is.

    No list pricing. The practical model is a per-screen or subscription fee offset by CPT 92229 reimbursement, plus camera capital cost, but AEYE Health does not publish rates, so buyers must negotiate blind.

    AEYE Health Pricing

    Practice SizeMonthly (per provider)ImplementationNotes
    Solo / Small / Mid / Enterprise Contact vendor Contact vendor No public rate card. Economics are usually framed around CPT 92229 reimbursement per screen plus camera acquisition, so the effective cost depends on screening volume.

    Pricing is indicative. Always request a formal quote and ask about module, interface, and annual maintenance fees.

    Key Features

    Autonomous AI Diagnosis

    AEYE-DS returns a diabetic retinopathy result without a human grader, which is what allows a non-specialist clinic to bill and act on the screen the same day.

    Handheld and Tabletop Camera Support

    Works with portable handheld cameras as well as robotic tabletop units, so a clinic can match hardware to room layout and patient mobility.

    Rapid Exam Workflow

    One image per eye with a result in roughly a minute, designed to fit inside a standard office visit rather than a separate screening appointment.

    No Pupil Dilation

    Undilated imaging removes the wait time and patient discomfort that historically killed in-office retinal screening programs.

    EHR Connectivity

    Epic integration is the primary documented path for pushing results into the patient record; other EHR coverage is less clear.

    Reimbursement and Quality Support

    Built around CPT 92229 billing and HEDIS diabetic eye exam gap closure, which is the commercial justification most buyers use.

    Fit

    Specialties Served

    Integrations & Compliance

    Capabilities

    aiDiagnostics retinalImaging pointOfCare fdaCleared

    Systems It Connects To

    Compliance

    ItemStatusNote
    ONC Certified Health IT No Not listed in the ONC CHPL active database.
    FDA cleared Yes 510(k) clearance for autonomous detection of more than mild diabetic retinopathy; this is the regulatory basis for the whole product.
    HIPAA Not published No public HIPAA statement or BAA documentation surfaced; enterprise buyers should request it directly.

    AEYE Health Pros & Cons

    Pros

    • FDA-cleared autonomous read removes the specialist over-read bottleneck.
    • Supports handheld cameras, which lowers the barrier for smaller clinics.
    • Clear reimbursement story under CPT 92229 and alignment with HEDIS eye exam measures.
    • Epic integration fits the EHR footprint of its target customers.
    • Focused on the highest-volume care gap in diabetic screening rather than a broad, unfocused AI portfolio.

    Cons

    • No public pricing, so buyers cannot budget without a sales cycle.
    • Support model, SLAs, and security certifications are undocumented.
    • Single cleared indication in the US; the broader AEYE-X platform is not commercially available domestically.
    • Crowded autonomous screening category with IDx-DR and EyeArt holding comparable clearances.
    • Smaller commercial footprint and installed base than legacy retinal imaging incumbents.

    IDx-DR (Digital Diagnostics)

    The other well-known FDA-cleared autonomous diabetic retinopathy AI, but historically tied to a specific tabletop camera, which is a constraint for mobile or space-limited clinics.

    Eyenuk (EyeArt)

    Competing cleared autonomous screening system with a broader retinal image base and its own camera partnerships; a common head-to-head in health system evaluations.

    Compare AEYE Health vs Eyenuk (EyeArt) →

    Explore EHR Software Ecosystem: Integrations, Partners & Add-Ons Compare AEYE Health with other Endocrinology and Ophthalmology EHR vendors or browse the full EHR & Healthcare Technology Solutions Index.

    Are you AEYE Health? Claim your vendor profile, add product details, and reach practices researching EHRs. Claim Profile/Get Listed

    Spotted an error? We publish this data as-is from CMS sources. If a practice or vendor listing is wrong, email support@ehratlas.com and we'll review it.

    About This Data & Methodology

    Source: This profile is assembled from the vendor's public website (features, capabilities, customer stories, media, and product updates) and EHRAtlas analyst evaluation. Compliance claims, pricing, and integration details should be verified directly with the vendor before making a purchase decision.

    Methodology: Where available, we extract structured facts (customers, outcomes, integrations, security certifications) directly from the vendor's own published pages. Claims are linked to their source. Scores reflect analyst judgment based on available public evidence and are not endorsements.

    Updates: Vendors are re-scanned periodically. Profile last reviewed on the date shown in the hero.

    Corrections: If you spot an error or a change in the vendor's product, capabilities, or pricing, email us and we'll review it.

    Spotted an error or need to submit a correction? Email support@ehratlas.com.

    ✨ EHR Matchmaker Visit AEYE Health ↗ For vendors: Claim profile →